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Abstract: Substantial efforts to eliminate or reduce latent HIV-1 reservoirs are underway in clinical
trials and have created a critical demand for sensitive, accurate, and reproducible tools to evaluate
the efficacy of these strategies. Alternative reservoir quantification assays have been developed to
circumvent limitations of the quantitative viral outgrowth assay. One such assay is tat/rev induced
limiting dilution assay (TILDA), which measures the frequency of CD4+ T cells harboring inducible
latent HIV-1 provirus. We modified pre-amplification reagents and conditions (TILDA v2.0) to improve
assay execution and first internally validated assay performance using CD4+ T cells obtained from
cART-suppressed HIV-1-infected individuals. Detection of tat/rev multiply spliced RNA was not altered
by modifying pre-amplification conditions, confirming the robustness of the assay, and supporting the
technique’s amenability to limited modifications to ensure better implementation for routine use in
clinical studies of latent HIV-1 reservoirs. Furthermore, we cross-validated results of TILDA v2.0 and the
original assay performed in two separate laboratories using samples from 15 HIV-1-infected individuals.
TILDA and TILDA v2.0 showed a strong correlation (Lin’s Concordance Correlation Coefficient = 0.86).
The low inter-laboratory variability between TILDAs performed at different institutes further supports
use of TILDA for reservoir quantitation in multi-center interventional HIV-1 Cure trials.
Keywords: HIV-1 latency; reservoir quantification; inducible reservoirs; TILDA; assay performance
1. Introduction
Novel experimental approaches designed to reduce or eliminate long-lived Human
Immunodeficiency Virus type 1 (HIV-1) reservoirs are increasingly being tested in clinical trials,
creating a demand for sensitive, accurate and reproducible assays to evaluate their potential
effect on the size of the latent reservoir [1]. The quantitative viral outgrowth assay (QVOA) is
used to measure the frequency of replication-competent proviruses that persist in a population of
resting memory CD4+ T cells [2,3]. Although QVOA is considered the “gold standard”, this assay
underestimates the size of the latent reservoir due to suboptimal induction of all replication-competent
Viruses 2020, 12, 973; doi:10.3390/v12090973 www.mdpi.com/journal/viruses
Viruses 2020, 12, 973 2 of 9
proviruses [4,5]. Simplified QVOA approaches, which are easier to perform, have been developed [2,6,7],
but leukapheresis or large blood draws (up to 200 mL) are required to obtain sufficient amounts of
input cells, due to the low frequency of latently infected cells (~1 replication-competent provirus per
million resting CD4+ T cells). Furthermore, poor reproducibility and scalability limit its widespread
use in clinical trials [7–9]. Alternatively, total HIV-1 DNA quantification using real-time or digital
droplet PCR is straightforward and frequently used to determine HIV-1 reservoir size in clinical
studies [10]. However, this technique largely overestimates reservoir size, because >98% of the
proviruses detected are not replication-competent. Consequently, this assay is not suitable to
study interventions that reduce the size of the replication-competent reservoir [5]. Alternative
methods are under development to circumvent these limitations in estimating HIV-1 reservoir
size. These include assays that quantify the amount of latently infected cells with inducible
provirus (transcription-competent) or the number of cells capable of expressing viral proteins
(translation-competent) [11–16]. However, these techniques also require large blood draws to get a
sufficient amount of input cells (10–15 million CD4+ T cells) [12], which may not always be available
in interventional clinical studies. A well-established inducible reservoir assay (tat/rev induced limiting
dilution assay [TILDA]), which requires a minimum of 10–20 mL of blood, was developed to measure
the frequency of CD4+ T cells expressing tat/rev multiply spliced RNA (msRNA), either constitutively
or upon in vitro stimulation [17]. Although tat/rev msRNA expression does not exclusively translate
into the production of infectious virions, the likelihood of quantifying defective proviruses with
extensive internal deletions [5] is largely reduced. Indeed, TILDA holds great promise for application
in clinical trials as it requires less input cells (<1 million CD4+ T cells) and can be completed within
two days. The assay has a broad dynamic range (up to 3 logs), an inter-assay coefficient of variation
(CV) of 21%, and a limit of detection (LOD) of 1.4 inducible reservoir cells per million CD4+ T cells [17].
However, in order for TILDA to be implemented in multi-center studies, it is essential to validate that
this assay can be conducted within the unique infrastructure of each of the independent laboratories
that preferentially use a fixed set of reagents, without compromising its reproducibility.
Here, we report that TILDA is amenable to limited modifications to facilitate its implementation
for routine use in clinical studies of latent HIV-1 reservoirs. We also report the first evidence of low
inter-laboratory variability between TILDAs performed at different institutes, thereby advocating its
use for reservoir quantitation in multi-center interventional HIV-1 Cure trials.
2. Materials and Methods
2.1. Participants and Sample Collection
Samples from 36 HIV-1-infected individuals, >18 years of age on suppressive combination
antiretroviral therapy (cART) with plasma HIV-1 RNA <50 copies/mL for at least six months were tested
in this study. Except for one individual, all participants initiated cART during chronic HIV-1 infection.
Peripheral blood mononuclear cells (PBMCs) were isolated from blood or leukapheresis samples by
Ficoll density gradient centrifugation and were cryopreserved in liquid nitrogen. The characteristics of
the study participants are detailed in Table S1.
2.2. Ethics Statement
Written informed consent was obtained from all participants. The use of samples for the study
was approved by Erasmus MC Medical Ethics Committee (MEC-2005-227 [22 March 2006] and
MEC-2016-148 [22 July 2016]).
2.3. Quantitative Plasma HIV-1 RNA Measurements
Plasma HIV-1 RNA was measured using a commercial HIV-1 RNA quantification assay
(COBAS® Ampliprep/COBAS® Taqman® HIV-1 Test v2.0, Roche Molecular Systems, Inc., Branchburg,
NJ, USA) with a quantification limit of 20 copies/mL.
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2.4. TILDA
TILDA was performed as initially described [17] or with several modifications (TILDA v2.0).
Total CD4+ T cells were isolated from thawed PBMCs by negative magnetic selection using the EasySep
Human CD4+ T cell Enrichment kit (STEMCELL Technologies, Vancouver, BC, Canada). CD4+ T cells
were resuspended at 2 × 106 cells/mL in complete RPMI-1640 (Lonza, Basel, Switzerland) supplemented
with 10% Fetal Calf Serum (Sigma-Aldrich, Darmstadt, Germany) and 1% Penicillin/Streptomycin
(Lonza, Basel Switzerland) and rested for 3 h at 37 ◦C and 5% CO2 prior to stimulation with 100 ng/mL
phorbol 12-myristate 13-acetate (PMA) and 1 µg/mL ionomycin (both from Sigma-Aldrich, Darmstadt,
Germany). After 12–14 h of stimulation, CD4+ T cells were washed in RPMI-1640, counted and serially
diluted to 1.8 × 106 cells/mL, 9 × 105 cells/mL, 3 × 105 cells/mL and 1 × 105 cells/mL in RPMI-1640.
From each dilution, 10 µL of the cell suspension was distributed to 22–24 wells of a 96-well plate
containing 2 µL One-step RT-PCR enzyme (QIAGEN, Hilden, Germany), 10 µL 5× One-step RT-PCR
buffer (QIAGEN, Hilden, Germany), 10 µL Triton-x100 (0.3%) (Sigma-Aldrich), 0.25 µL RNAsin (40 U/µL)
(Promega, Leiden, The Netherlands), 2 µL dNTPs (10 mM each), 1 µL of forward and reverse primers [17]
tat 1.4 and rev (both at 20 µM), and nuclease-free water to a final volume of 50 µL. A positive template
control (in vitro-transcribed tat/rev RNA template) or ACH-2 cells (obtained through NIH AIDS reagent
program, Germantown, MD, USA) and negative template control (nuclease free water) were added to
two separate wells in each run. The primers (Eurogentec, Seraing, Liege, Belgium) and probe (Integrated
DNA Technologies, Leuven, Belgium) used to detect multiply spliced tat/rev RNA are as described
previously [17]. The one-step reverse transcription (RT)-PCR was run in a thermocycler (1000-series,
Bio-Rad, Veneendal, The Netherlands) using the following thermocycling conditions: reverse transcription
at 50 ◦C for 30 min, denaturation at 95 ◦C for 15 min, followed by 25 cycles of 95 ◦C for 30 s, 55 ◦C for
1 min and 72 ◦C for 2 min, and a final extension at 72 ◦C for 5 min. After one-step RT-PCR, 2 µL of the 1st
PCR product was directly used as input for the tat/rev semi-nested real-time PCR reaction, which consisted
of 5 µL 4× Taqman Fast Advanced Master Mix (Thermo Fisher Scientific, Landsmeer, The Netherlands),
0.4 µL of each primer (tat 2.0 and rev, both at 20 µM), 0.4 µL TILDA probe (5 µM), as published in [17],
and nuclease-free water to a final reaction volume of 20 µL. The real-time PCR was performed in a
LightCycler 480 Instrument II (Roche, Almere, The Netherlands) using the following conditions: 5 min at
50 ◦C (UNG step), 95 ◦C for 20 s, followed by 45 cycles of 95 ◦C for 3 s and 60 ◦C for 30 s. Positive wells at
each dilution were counted, and the maximum likelihood method was used to determine the frequency
of cells with inducible HIV-1 tat/rev msRNA using ELDA, a software application for extreme limiting
dilution analysis [18] The major differences between the two TILDA methods are presented in Table 1.
Table 1. Major differences in RT-qPCR conditions in the two versions of TILDA.
Characteristic TILDA TILDA v2.0
Input volume of cells per
reaction 1 1 µL 10 µL
One-step RT-PCR reagents
Superscript III Platinum Taq (Life Technologies)
& Buffer, RNase inhibitor (Life Technologies),
Tris-EDTA (TE) buffer
HotStarTaq DNA Polymerase, Sensiscript and
Omniscript Reverse Transcriptases & Buffer
(QIAGEN), RNasin Ribonuclease Inhibitor
(Promega), 0.1% solution of Triton X-100
Final reaction volume 11 µL 50 µL
Cycling conditions 50
◦C for 15 min, 95 ◦C for 2 min, 24 cycles of
amplification (95 ◦C 15 s, 60 ◦C 4 min)
50 ◦C for 30 min, 95 ◦C for 15 min, 25 cycles of
amplification (95 ◦C 30 s, 55 ◦C 1 min, 72 ◦C
2 min) final extension at 72 ◦C for 5 min
Input volume of pre-amplified
product per reaction 1 µL of 1:5 dilution 2 µL
Real-time PCR reagent LightCycler 480 Probe Master buffer (RocheApplied Sciences)
Custom TaqMan Fast Advanced Master Mix
(Thermo Fisher Scientific)
Final reaction volume 10 µL 20 µL
Cycling conditions 95
◦C for 10 min, 45 cycles of 95 ◦C 10 s, 60 ◦C
30 s, 72 ◦C 1 s and a cooling step at 40 ◦C for 30 s
50 ◦C for 5 min (UNG step), 95 ◦C for 20 s,
45 cycles of 95 ◦C for 3 s and 60 ◦C for 30 s
1 Cells are serially diluted and then distributed in replicates of 18,000, 9000, 3000 and 1000 per well with the indicated
volume. Primers and probe as published [17].
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2.5. Tat/rev RNA Standard and Cell Lines Used for Assay Validation
A gBlock containing a sequence of the tat/rev target region was synthesized by Integrated DNA
Technologies (Leuven, Belgium) and in vitro RNA transcripts were generated using T7 Ribomax
(Promega, Leiden, The Netherlands) and Turbo DNA-free kits according to manufacturer instructions
(Ambion, Life Technologies, Landsmeer, The Netherlands). Serial dilutions of the DNase-treated
synthetic tat/rev RNA were tested by qPCR with and without a reverse transcription step. The highest
dilution that tested negative without RT and positive after RT was used as the final working stock.
RNA concentration of this stock was determined using Qubit RNA HS Assay Kit (Invitrogen, Landsmeer,
The Netherlands) and used to estimate copy numbers. ACH-2 cells (obtained from Thomas Folks
through the AIDS reagent program, Division of AIDS, NIAID, NIH, Germantown, MD, USA) [19,20]
and uninfected CD4+ T cells were maintained in complete RPMI-1640.
2.6. Statistical Analysis
Wilcoxon’s matched-pairs test was used to compare the median estimates generated from TILDA
and TILDA v2.0. Lin’s Concordance Correlation analysis was used to compare the two methods
and Bland-Altman plots to determine the limit of agreement. Statistical analyses were carried out
using GraphPad Prism 5 Software (San Diego, CA, USA) and MedCalc Software (Ostend, Belgium).
Two-tailed p-values of <0.05 were considered statistically significant.
3. Results
3.1. TILDA Is Amenable to Limited Modifications without Compromising Analytical and Clinical Sensitivity
We modified TILDA as described in Table 1 to improve its implementation for routine use in
clinical studies of latent HIV-1 reservoir analysis. To evaluate whether modifying the pre-amplification
reagents and conditions would alter analytical sensitivity, we compared the capacity to detect serial
dilutions of a synthetic tat/rev RNA template using reference (TILDA) or TILDA v2.0 RT-qPCR reagents
and conditions. Regardless of the reagents used, there was no difference in detection of the tat/rev
RNA standard at any dilution (p > 0.35) (Figure 1A). Additionally, when we compared target detection
using different reaction volumes of the one-step RT-PCR kits (25 µL or 50 µL (QIAGEN) and 11 µL
(Superscript III Platinum), there was a strong correlation (R2 ≥ 0.99) between the cycle threshold (Ct)
values obtained for both kits (Figure 1B). We opted for 50 µL as the final reaction volume for the
one-step RT-PCR, which permits larger sample input volumes, minimizing pipetting imprecisions.
To evaluate TILDA v2.0 performance in clinical samples, we isolated CD4+ T cells from PBMC obtained
from 36 HIV-1-infected individuals, suppressed on cART for more than six months. Tat/rev msRNA was
detected in 31 out of 32 (96.9%) HIV-1 subtype B samples tested. Samples from individuals infected
with undetermined or non-B HIV-1 subtype (n = 4) were excluded from further analysis, as tat/rev
msRNA is less efficiently detected due to primer and probe specificity for subtype B viruses. However,
two of these samples had detectable levels of tat/rev msRNA. The frequencies of CD4+ T cells expressing
tat/rev msRNA from 32 individuals with subtype B infection are shown in Figure 1C. The median
frequency of cells expressing tat/rev msRNA was 23.95 cells per million CD4+ T cells (Range: 1.4–362).
The inter-assay coefficient of variation (CV) for TILDA v2.0 was 24.5% (Range: 9–62%) (Figure 1D),
which is comparable to that of the original assay (CV = 21%) [17]. We measured cell viability of two
independent replicates for each sample after stimulation with PMA and Ionomycin and observed no
apparent correlation between the CV and difference in cell viability. Overall, modifications of the
RT-qPCR did not alter the detection of tat/rev msRNA and subsequent quantification of the inducible
reservoir in clinical samples, demonstrating that this technique is amenable to modifications to facilitate
personalized application in clinical settings.
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kits is shown. Statistical significance is determined by p < 0.05. (C) Quantification of inducible HIV-1 
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variation (CV) determined from TILDA measurements of four individuals. Mean CV= 24.5%. The 
Figure 1. TILDA analytical and clinical sensitivity. (A) Detection of serial dilutions of a synthetic
tat/rev RNA template in the absence of cells using the original TILDA RT-qPCR conditions compared to
the TILDA v2.0 RT-qPCR conditions. Three wells per dilution were tested based on cycle threshold
(Ct) values. NTC = Negative template control. A multiple paired t-test was used to compare mean
Ct values. The error bars represent the SD of the mean of two independent runs. (B) Dilutions of
10–10,000 copies of tat/rev RNA were pre-amplified using different reaction volumes using QIAGEN
(25 µL; open circles, and 50 µL; closed circles) or Superscript III Platinum one-step RT kits. Three wells
per dilution were tested for positivity. A Pearson’s correlation test between the reference and two
test kits is shown. Statistical significance is determined by p < 0.05. (C) Quantification of inducible
HIV-1 reservoirs in clinical samples. Frequency of CD4+ T cells expressing tat/rev msRNA after in vitro
stimulation with PMA/Ionomycin (N = 32 HIV-1-infected individuals on suppressive cART). Target was
not detected for one sample, indicated using an open circle. The median and interquartile range is
shown (the median frequency of cells with inducible tat/rev msRNA per million CD4+ T cells = 23.95).
The dotted line represents the assay limit of detection (LOD). (D) The inter-assay coefficient of variation
(CV) determined from TILDA measurements of four individuals. Mean CV= 24.5%. The other numbers
represent the CV for each individual calculated from a minimum of two independent measurements.
The error bars represent SD of the mean.
3.2. TILDA Shows High Inter-Laboratory Reproducibility
In an inter-laboratory assessment of TILDA and TILDA v2.0, cryopreserved PBMCs were shipped
from Erasmus MC in Rotterdam to CHUV, Department of Immunology and Allergy in Lausanne,
to compare the estimated frequencies of CD4+ T cells expressing tat/rev msRNA in a subset of samples
(n = 15). A different operator performed TILDA according to the initially described protocol [17].
As shown in Figure 2A, there was no significant difference in the median estimate and IQR for the
two versions (p = 0.8552), which correlated well (Lin’s Concordance Correlation Coefficient = 0.86,
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Coefficient of bias = 0.95) (Figure 2B). A Bland–Altman plot revealed a strong agreement between the two
versions of the assay (mean difference = −0.14 log10 with 86.6% of the data points falling within the 95%
Limits of agreement (LOA) −1.15 to 0.87 log10) (Figure 2C). These data support the cross-comparison
of TILDA results generated by different methods performed in different laboratory settings.
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Figure 2. TILDA inter-laboratory reproducibility. (A) The frequency of CD4+ T cells expressing tat/rev
msRNA after in vitro stimulation with PMA/Ionomycin in a subset of individuals (N = 15), quantified
by TILDA and TILDA v2.0. Each individual is represented by a different colored dot. The open
circles are below the LOD. Wilcoxon’s matched-pairs test was used to compare the medians. Statistical
significance is determined by p < 0.05. (B) Lin’s Concordance Correlation Coefficient (LCCC) plot.
The black dots represent inducible reservoir size quantified by TILDA and TILDA v2.0. The open circle
is below the LOD. The grey diagonal line represents the best-fit line. Coefficient of bias (Cb) is a measure
of accuracy. (C) Bland–Altman plot using log-transformed inducible reservoir size measurements
by the two assays. The open circle is below the LOD. The blue dotted line represents the mean bias,
and the red dotted lines represent the 95% limits of agreement.
4. Discussion
TILDA [17] is a widely adopted method used to measure latent HIV-1 reservoirs in different
groups of people living with HIV-1. Due to its low sample requirement and short turn-around time
compared to QVOA, TILDA is an appropriate alternative for quantifying the replication-competent
HIV-1 reservoir and allows easier longitudinal sample analysis. In this study, we modified TILDA to
increase its amenability for routine use in clinical studies of the latent HIV-1 reservoir and assessed
the inter-laboratory reproducibility of the initial and modified assay (TILDA v2.0). Our results
provide additional evidence that TILDA is amenable to modifications without compromising assay
performance, facilitating its routine implementation in diagnostic/laboratory settings that have already
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optimized/validated their protocols using a fixed set of RT-qPCR reagents. The robustness of TILDA
thus enables the recapture of available laboratory resources, resulting in the reinvestment of surplus
reagents and saving laboratory costs by purchasing reagents in larger volumes, which in the long
run may improve internal cost-effectiveness. Several others have also reported the optimization and
further development of TILDA either through the modification of primers to detect tat/rev msRNA
expressed from non-B HIV-1 subtypes, isolating RNA prior to RT-qPCR to improve assay sensitivity or
by enhancing the inducibility of tat/rev msRNA in CD4+ T cells from infants through the addition of
phytohemagglutinin and a longer duration of stimulation (18 instead of 12 h) [21–26]. Our method
increases the reaction volumes of alternative PCR reagents used to pre-amplify tat/rev msRNA to
permit larger sample volumes (10 µL compared to 1 µL in the initial TILDA protocol), which reduces
pipetting imprecisions. Moreover, cells may be dispensed using multi-step pipettes, reducing operating
time, which is critical because rapid processing of the sample is essential for minimizing tat/rev
msRNA degradation after stimulation and to avoid underestimating the reservoir size. Favorably,
pre-amplifying tat/rev msRNA in a 50 µL reaction volume compared to 11 µL in the initial TILDA
protocol eliminates the need to dilute the PCR products prior to target detection by real-time PCR.
This modification not only reduces several pipetting steps in the workflow, but also minimizes
the risk of cross-contamination when diluting the first amplification products, which is essential
because false positives would result in the overestimation of reservoir size. Therefore, we advocate
modifications such as those in TILDA v2.0 to improve the technical operation of the assay and
minimize errors in quantifying inducible reservoirs. While the inter-assay variation of TILDA was
determined in this study and in [17], there is no data yet on the assay’s inter-laboratory reproducibility.
Using 15 clinical samples, we report a strong agreement between the two TILDA methods with a Lin’s
Concordance Correlation Coefficient (LCCC) of 0.86. In contrast, QVOA, considered the reference
assay for replication-competent reservoir quantification, is more variable [7–9]. The variation observed
in QVOA measurements is attributable to several factors related to the complexity of the assay such as
the number of input cells and replicates, different potencies of activating compounds, the duration
of stimulation, different feeder cell type used to amplify reactivated virus and different methods
of readout [6,7,9,27–29]. Furthermore, applying Poisson distribution to detect rare cells harboring
replication-competent provirus is a major unavoidable source of variation and dictates the input
number of cells required [7,9]. With the development of newer techniques to quantify the reservoir, it is
imperative that each reservoir quantification method is extensively evaluated for assay performance
criteria such as specificity, sensitivity, and reproducibility within and between laboratories, alongside
scalability to assess the validity for their application in HIV-1 cure trials. Moreover, given the small
changes in reservoir size currently attainable with the available clinical interventions, the methods
developed should accurately and precisely measure reservoir dynamics in a reproducible manner in
multi-center clinical studies and longitudinal patient samples. Our data on negligible inter-laboratory
variability of TILDA despite limited modifications to the protocol to improve technical operation further
advocate the application of TILDA for reservoir quantification and cross-comparison of results from the
initial assay or modified versions performed in multi-center HIV-1 cure clinical trials. Further research
is warranted to investigate TILDA’s suitability for measuring reservoir dynamics in reservoir-reduction
clinical intervention studies.
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